Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22915934 | 0.90 | HPGD (0.51) | NAMPTHPGDNPC1CHRNB2CHRNB4 | |
| SCHEMBL20213867 | 0.87 | CDK4 (0.56) | NAMPTHPGDHTR2CDRD2DRD3 | |
| SCHEMBL20213921 | 0.84 | NAMPT (0.72) | NAMPTHTR2C | |
| SCHEMBL20214405 | 0.84 | NAMPT (0.57) | NAMPTHPGDHTR2CSLC6A7POLB | |
| SCHEMBL20214421 | 0.83 | NAMPT (0.56) | NAMPTHPGDHTR2C | |
| SCHEMBL22916012 | 0.79 | ALDH1A1 (0.53) | HPGDDRD2DRD3CA1CA2 | |
| SCHEMBL22915902 | 0.78 | KDM4E (0.48) | NAMPTNPC1GAA | |
| SCHEMBL22915968 | 0.78 | MAPK1 (0.60) | NAMPTHPGDNPC1POLBGAA | |
| SCHEMBL22915970 | 0.76 | POLB (0.55) | NAMPTHPGDHTR2CSLC6A7POLB | |
| SCHEMBL24229770 | 0.76 | NAMPT (0.47) | NAMPTHTR2CSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548613-A1 | BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS | Fraunhofer Gesellschaft zur Förderung der Angewand (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018100159-A1 | BACTERIAL GLUTAMINYL CYCLASES AND INHIBITORS THEREOF FOR USE IN THE TREATMENT OF PERIODONTITIS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | NAMPT 1158/4885HPGD 606/4885HTR2C 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.